Bank of America
AKBA icon

Bank of America’s Akebia Therapeutics AKBA Stock Holding History

Bank of America’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-115,000
Closed -$860K – 7078
2016
Q2 		$860K Buy
+115,000
New +$1M ﹤0.01% 4286

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America's AKBA Position: Q1 2026 in Review

Bank of America increased its Akebia Therapeutics (AKBA) stake by 22% in Q1 2026, buying an estimated $695K and bringing the position to 2,763,362 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3657.

Bank of America first reported a position in AKBA in Q3 2014 and has held it in 47 quarters since. The position peaked at $9.83M in Q1 2016. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Bank of America held 2,763,362 shares of Akebia Therapeutics worth $3.84M as of Q1 2026.
  • Bank of America bought 505,951 Akebia Therapeutics shares in Q1 2026, an estimated $695K.
  • Akebia Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3657 holding.
  • Bank of America first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 47 quarters since.
  • Bank of America's Akebia Therapeutics position peaked at $9.83M in Q1 2016.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.